Trial
NCT01515969
Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Heather Wakelee
Collaborators
Genentech, Inc.; Novartis
Condition
Non-small Cell Lung Cancer (NSCLC), Recurrent
Intervention
Erlotinib hydrochloride
Why stopped
Patient safety - Unacceptable toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-12